Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349783 | 0.84 | ERN1 (0.41) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL6060504 | 0.78 | ERN1 (0.42) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL16258877 | 0.75 | ERN1 (0.34) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL9947770 | 0.75 | ERN1 (0.46) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL21803292 | 0.75 | ERN1 (0.34) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL23890741 | 0.75 | ERN1 (0.31) | ERN1 | |
| SCHEMBL11179328 | 0.75 | ERN1 (0.43) | ERN1ALDH1A1TDP1 | |
| SCHEMBL6061080 | 0.73 | ERN1 (0.38) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL7271102 | 0.72 | KIF11 (0.39) | ERN1MEN1ALDH1A1KMT2ATDP1 | |
| SCHEMBL15273920 | 0.71 | MEN1 (0.37) | ERN1MEN1ALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4076443-B1 | SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUND AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20220396577-A1 | NOVEL SUBSTITUTED 1,3-8-TRIAZASPIRO[4,5] DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396577-A1 | NOVEL SUBSTITUTED 1,3-8-TRIAZASPIRO[4,5] DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4076443-A1 | NOVEL SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021126725-A1 | NOVEL SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126725-A1 | NOVEL SUBSTITUTED 1,3,8-TRIAZASPIRO[4,5]DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396577-A1 | NOVEL SUBSTITUTED 1,3-8-TRIAZASPIRO[4,5] DECANE-2,4-DIONE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) AND/OR TRYPTOPHAN 2,3-DIOXYGENASE (TDO) INHIBITORS | IDO1, IDO2, TDO2 | ERN1 4625/4885MEN1 3449/4885ALDH1A1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.